OMOBOLANLE AYOYINKA OMOTESO

Dr. OMOBOLANLE AYOYINKA OMOTESO


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
OOOMOBOLANLE AYOYINKA OMOTESO
OMOBOLANLE AYOYINKA OMOTESO
AFADEWALE FADAKA
ADEWALE FADAKA
RWRoderick Bryan Walker
Roderick Bryan Walker
SKSandile Maswazi Khamanga
Sandile Maswazi Khamanga
Multidrug-resistant tuberculosis (MDR-TB) is a significant public health challenge globally, exacerbated by the limited efficacy of existing therapeutic approaches, prolonged treatment duration, and severe side effects. As drug resistance continues to emerge, innovative drug delivery systems and treatment strategies are critical to combating this crisis. This review highlights the molecular mechanisms underlying resistance to drugs in Mycobacterium tuberculosis, such as genetic mutation, efflux pump activity, and biofilm formation, contributing to the persistence and difficulty in eradicating MDR-TB. Current treatment options, including second-line drugs, offer limited effectiveness, prompting the need for innovation of advanced therapies and drug delivery systems. The progression in drug discovery has resulted in the approval of innovative therapeutics, including bedaquiline and delamanid, amongst other promising candidates under investigation. However, overcoming the limitations of traditional drug delivery remains a significant challenge. Nanotechnology has emerged as a promising solution, with nanoparticle-based drug delivery systems offering improved bioavailability and targeted and controlled release delivery, particularly for pulmonary targeting and intracellular delivery to macrophages. Furthermore, the development of inhalable formulations and the potential of nanomedicines to bypass drug resistance mechanisms presents a novel approach to enhancing drug efficacy. Moreover, adjunctive therapies, including immune modulation and host-directed therapies, are being explored to improve treatment outcomes. Immunotherapies, such as cytokine modulation and novel TB vaccines, offer complementary strategies to the use of antibiotics in combating MDR-TB. Personalized medicine approaches, leveraging genomic profiling of both the pathogen and the host, offer promise in optimizing treatment regimens and minimizing drug resistance. This review underscores the importance of multidisciplinary approaches, combining drug discovery, advanced delivery system development, and immune modulation to address the complexities of treating MDR-TB. Continued innovation, global collaboration, and improved diagnostics are essential to developing practical, accessible, and affordable treatments for MDR-TB.

4 February 2022 in International Journal of Analytical Chemistry
Verified
Journal Article
Open access
PDF file
OOOMOBOLANLE AYOYINKA OMOTESO
OMOBOLANLE AYOYINKA OMOTESO
MMMarnus Milne
Marnus Milne
MAMarique Aucamp
Marique Aucamp
An effective analytical method is requisite to ensure the accurate identification and quantification of drug(s), either in bulk material or in complex matrices, which form part of finished pharmaceutical products. For the purpose of a pharmaceutical formulation study, it became necessary to have a simple, yet robust and reproducible reversed-phase HPLC method for the simultaneous detection and quantification of lamivudine (3TC), tenofovir disoproxil fumarate (TDF), and dolutegravir sodium (DTG) in bulk form, complex polymeric matrices, and during drug release studies. A suitable method was developed using a Kinetex® C18, 250×4.6mm column as stationary phase and a mobile phase consisting of 50:50 v/v methanol and water with 1mL orthophosphoric acid, with a flow rate of 1.0mL/min and column temperature maintained at 35°C. A detection wavelength of 260nm and an injection volume of 10μL were used. The method was validated according to the International Conference on Harmonization (ICH) guideline Q2 (R1), and the parameters of linearity and range, accuracy, precision, specificity, limit of detection (LOD), limit of quantification (LOQ), robustness, and stability were all determined. Acceptable correlation coefficients for linearity (R2) of >0.998 for each of the three drugs were obtained. The LOD was quantified to be 56.31μg/mL, 40.27μg/mL, and 7.00μg/mL for 3TC, TDF, and DTG, respectively, and the LOQ was quantified as 187.69μg/mL, 134.22μg/mL, and 22.5μg/mL for 3TC, TDF, and DTG, respectively. In relation to all the determined validation parameters, this method proves to be suitable for the accurate identification and quantification of the three ARVs, either alone or in combination, as well as when incorporated into polymeric matrices. Furthermore, the method proves to be suitable to detect degradation of the compounds.

3 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
OOOMOBOLANLE AYOYINKA OMOTESO
OMOBOLANLE AYOYINKA OMOTESO
AFADEWALE FADAKA
ADEWALE FADAKA
RWRoderick Bryan Walker
Roderick Bryan Walker
SKSandile Maswazi Khamanga
Sandile Maswazi Khamanga
Multidrug-resistant tuberculosis (MDR-TB) is a significant global public health challenge, exacerbated by the limited efficacy of existing therapeutic approaches, prolonged treatment duration and severe side effects. As drug resistance continues to emerge, innovative drug delivery systems and treatment strategies are critical to combating this crisis. This review highlights the molecular mechanisms underlying resistance to drugs in Mycobacterium tuberculosis, such as genetic mutation, efflux pump activity and biofilm formation, contributing to the persistence and difficulty in eradicating MDR-TB. Current treatment options, including second-line drugs, offer limited effectiveness, prompting the need for innovation of advanced therapies and drug delivery systems. The progression in drug discovery has resulted in the approval of innovative therapeutics, including bedaquiline and delamanid amongst other promising candidates under investigation. However, overcoming the limitations of traditional drug delivery remains a significant challenge. Nanotechnology has emerged as a promising solution, with nanoparticle-based drug delivery systems offering improved bioavailability, targeted and controlled release delivery particularly for pulmonary targeting and intracellular delivery to macrophages. Furthermore, the development of inhalable formulations and the potential of nanomedicines to bypass drug resistance mechanisms presents a novel approach to enhancing drug efficacy. Moreover, adjunctive therapies, including immune modulation and host-directed therapies, are being explored to improve treatment outcomes. Immunotherapies, such as cytokine modulation and novel TB vaccines, offer complementary strategies to the use of antibiotics in combating MDR-TB. Personalized medicine approaches, leveraging genomic profiling of both the pathogen and the host, offer promise in respect of optimization of treatment regimens and minimizing drug resistance. This review underscores the importance of multidisciplinary approaches, combining drug discovery, advanced delivery system development and immune modulation to address the complexities of treating MDR-TB. Continued innovation, global collaboration, and improved diagnostics are essential to developing effective, accessible, and affordable treatments for MDR-TB.

28 April 2023 in Future Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
TATolulope O. Ajala
Tolulope O. Ajala
OOOMOBOLANLE AYOYINKA OMOTESO
OMOBOLANLE AYOYINKA OMOTESO
OAOladotun M. Awe
Oladotun M. Awe
Background: Starch nanoparticle derivatives are gaining popularity as drug delivery vehicles because of their biocompatibility, better mechanical characteristics, heat stability properties, impediment qualities, permeability capabilities, and flexibility to be changed for specific predetermined functions. The effect of techniques and processing time on the physiochemical and drug release characteristics of sweet potato (Ipomoea batatas) starch nanoparticles and their ciprofloxacin-loaded nanoformulations was studied. Results: Scanning electron microscopy confirmed that the treated starch formed nanoparticles and also revealed significant changes in the morphology of the treated starches. The water absorption capacity of chemically treated starch nanoparticles (CTSN)-3 days was the highest, whereas CTSN-6 days had the maximum solubility. The functional groups present in the starch nanoparticles were confirmed by Fourier transform infrared spectroscopy and Raman. The thermal characteristics of starch nanoparticles were established using hot-stage microscopy, differential scanning calorimetry, and thermogravimetric analysis. The percentage drug content and loading efficiency of the model drug were extensively boosted by the chemical and mechanical treatment of Ipomoea batatas starch. In comparison with the untreated potato starch (UPS), release times for loaded drug were significantly longer for the chemically treated starch nanoparticles and mechanically treated starch nanoparticles (MTSN) starches in the rank order of T80%, CTSN-3 days > MTSN-3 days > CTSN-6 days > MTSN-6 days > UPS. The main kinetics of drug release were Fickian diffusion. Conclusion: After 3 days of acid hydrolysis, sweet potato starch yielded nanoparticulate carriers that can be employed for controlled or extended release of medicines that are poorly water soluble.

12 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
OOOMOBOLANLE AYOYINKA OMOTESO
OMOBOLANLE AYOYINKA OMOTESO
SKSandile Maswazi Khamanga
Sandile Maswazi Khamanga
RWRoderick Bryan Walker
Roderick Bryan Walker
This study applied the Alpha Astree II electronic tongue (E-tongue) to characterize and longitudinally monitor the taste profiles of four commercially available South African milk brands, ultra-pasteurized and UHT-processed, full-cream and low-fat variants, purchased across three seasons: late summer (March 2025), winter (June 2025), and spring (September 2025) in Makhanda, Eastern Cape. Forty-eight samples were analyzed on Days 0, 4, and 45 post-opening. Three-dimensional principal component analysis (PCA) score plots achieved cumulative variances exceeding 99.7%. Discriminant function analysis (DFA) score plots demonstrated complete visual separation of the three seasonal clusters with no inter-seasonal overlap; as no cross-validation was applied, DFA outputs reflect training-set group separability rather than validated predictive performance. Three distinct seasonal electrochemical fingerprints were identified at Day 0, with inter-seasonal separation retained at Day 45 despite advanced deterioration in quality. Winter milk consistently registered the highest CTS (saltiness) and NMS (umami) sensor responses across all brands during refrigerated storage. A universal crossover in AHS (sourness) and SCS (bitterness) dominance from spring at Day 0 to late summer at Day 4 was confirmed as a brand-independent seasonal signature across all UHT brands. Seasonal purchase batch was a consistent, brand-independent determinant of E-tongue taste fingerprint and post-opening sensor response trajectory, with direct implications for quality monitoring in dairy markets with variable cold-chain provision.

15 May 2024 in Proceedings
Verified
Conference Paper
Open access
PDF file
OOOMOBOLANLE AYOYINKA OMOTESO
OMOBOLANLE AYOYINKA OMOTESO
YGYusuf Oluwagbenga Ghazali
Yusuf Oluwagbenga Ghazali
MOMichael Ayodele Odeniyi
Michael Ayodele Odeniyi
To develop an active drug into a suitable dosage form, pharmaceutical scientists combine various excipients (additives) obtained from different sources